1546 results about "Secretion" patented technology

The invention discloses a self-adaptive intestinal function adjusting system based on biological feedback, and relates to the technical field of intestinal function adjustment, the self-adaptive intestinal function adjusting system comprises a signal acquisition module, a data analysis module, an adjustment feedback module and a user interaction module; the signal acquisition module adopts a multi-sensor fusion algorithm and a multi-source sensor to acquire intestinal function state information; wherein the multi-source sensor comprises a pressure sensor, a peristaltic sensor and a nerve sensor. The intestinal function self-adaptive adjusting system based on biological feedback can comprehensively collect biological signals of intestinal tracts, including pressure, peristalsis, nervous system signals and chemical substance secretion signals; the multi-dimensional monitoring mode can reflect the real state of the intestinal function more accurately, the limitation of a single sensor is avoided, and a rich and accurate data basis is provided for subsequent analysis and adjustment.

The invention belongs to the technical field of microorganisms, and relates to a lactobacillus paracasei JNL0025 strain and application thereof. Compared with a commercial strain lactobacillus casei substitute strain, the lactobacillus paracasei JNL0025 provided by the invention has the advantages that the guanine nucleoside conversion rate is improved, the inhibition rate of supernate on XOD is equivalent, and the inhibition on PNP activity can be realized; according to the lactobacillus paracasei JNL0025 disclosed by the invention, the lactobacillus paracasei JNL0025 has the effects of reducing the tendency of pro-inflammatory M1 type macrophages, increasing the proportion of anti-inflammatory M2 type macrophages and inhibiting secretion of pro-inflammatory cytokines TNF-alpha and IL-6, and the lactobacillus paracasei JNL0025 has a better inflammation inhibition effect than the lactobacillus rhamnosus LGG; animal experiment results show that the lactobacillus paracasei JNL0025 provided by the invention can significantly reduce the blood uric acid level of a hyperuricemia model mouse, alleviate the kidney inflammation level and alleviate DSS-induced colitis, and shows a huge application value.

The invention discloses bifidobacterium animalis subsp. Lactis BLa79 as well as application, a product and a method thereof, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium animalis subsp. Lactis BLa79 is CGMCC (China General Microbiological Culture Collection Center) NO. 32426, and the preservation number of the bifidobacterium animalis subsp. Lactis BLa79 is CGMCC NO. 32426. Based on the strain, the invention also provides application and related products of the strain. The BLa79 strain has broad-spectrum antibacterial performance, has the function of regulating intestinal flora, can effectively relieve ulcerative colitis, and can relieve colitis by increasing body weight, reducing DAI score, reducing spleen index, inhibiting colonic atrophy, reducing proinflammatory factor level and promoting SIgA secretion.

The invention belongs to the technical field of microorganisms, and relates to high-activity plant lactobacillus KL100 for relieving anxiety and depression and application of the high-activity plant lactobacillus KL100. The plant lactobacillus provided by the invention is KL100, is preserved in the China General Microbiological Culture Collection Center (CGMCC), has a preservation number of CGMCC No.27192, and is classified and named as the plant lactobacillus. The plant lactobacillus is KL100, has a good gastrointestinal passing rate, shows a breeding characteristic in the stomach after being embedded, is improved in cholate-resistant survival rate, and can be used for preparing the plant lactobacillus. According to the application disclosed by the invention, the expression of IL-1beta and TNF-alpha in a mouse body can be effectively reduced, the expression of IL-10 can be improved, and the secretion of 5-hydroxytryptamine by chromaffin cells in intestinal tracts can be promoted, so that anxiety and depression can be relieved, the strain resource is expanded, the development of the biological medicine field is promoted, and a new direction is provided for treating anxiety and depression.

The invention provides a catechol functionalized gelatin microsphere and application of the catechol functionalized gelatin microsphere in preparation of a product for inhibiting formation of subcutaneous effusion and promoting tissue repair, and relates to the technical field of biological materials.According to the designed and prepared catechol functionalized gelatin microsphere, catechol groups are introduced into the gelatin microsphere, and the catechol functionalized gelatin microsphere is prepared; good liquid absorption performance and biodegradability are realized. Cell experiment results show that the catechol functionalized gelatin microspheres have super multiple interfaces and can promote cell adhesion and proliferation, and the loose structure of the catechol functionalized gelatin microspheres can promote cell migration. In-vivo rabbit chest wall defect repair experiment results show that the catechol functionalized gelatin microspheres not only can inhibit formation of subcutaneous effusion, but also can collect autologous cells in situ and promote proliferation of the autologous cells and secretion of extracellular matrixes (such as collagen). The results show that the catechol functionalized gelatin microsphere material has clinical application potentials of inhibiting formation of subcutaneous effusion and promoting healing of subcutaneous wounds.

The invention discloses a plant lactobacillus JNL0074 strain, application thereof and a microbial agent, and belongs to the technical field of microorganisms. The lactobacillus plantarum JNL0074 is preserved in the China General Microbiological Culture Collection Center on June 24, 2024, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, the preservation number is CGMCC NO: 31047, and the lactobacillus plantarum is classified and named as lactobacillus plantarum. The strain can realize high yield of indole-3-lactic acid in an MRS culture medium. An in-vitro experiment result shows that supernate of the strain remarkably inhibits inflammatory polarization of macrophages stimulated by lipopolysaccharide and secretion of inflammatory factors. Animal experiment results show that the strain can significantly inhibit sodium dextran sulfate induced colonic tissue inflammatory factor secretion and intestinal barrier injury, alleviate ulcerative colitis, and show a huge application value.

The invention belongs to the technical field of medical sampling, and discloses a gynecological vaginal secretion sampling device which comprises a shell, a sealing cover mechanism, a support mechanism and a sampling mechanism. According to the device, after the shell is taken down, the support mechanism and the sampling mechanism are inserted into the lower body of a patient, then normal saline is injected into the fixing pipe through the liquid injection pipe, and the normal saline expands along with the injection of liquid into the liquid bag, so that an inner plate is pushed to move towards the inner wall of the supporting shell, and then a rubber plate is driven to move outwards; after the rubber plate is in contact with the inner wall of the vagina of the patient, injection of the normal saline is stopped, then the outer cover is rotated to drive the gear to rotate, and the gear drives the rotating rod in the gear to rotate, so that the sampling cotton blocks rotate to dip secretions in the vagina of the patient; by arranging the rotating rods, secretions of different depths of a patient can be sampled through the single rotating rod, secretions of different positions can be sampled through the device due to the arrangement of the multiple rotating rods, and therefore samples are richer.

The invention discloses application of Lactobacillus reuteri CCFM1289 with high yield of indoleacetic acid in relieving anxiety and depression, and belongs to the technical field of microorganisms. The Lactobacillus reuteri CCFM1289 can produce heteroauxin at high yield in vivo and in vitro, promote the yield of heteroauxin in fecal flora, relieve anxiety-like and depression-like behaviors of depression mice, relieve HPA hyperfunction, improve the level of brain-derived neurotrophic factor BDNF in hippocampus, promote secretion of 5-HTP and 5-HT in brain, improve the content of heteroauxin in colon, serum and brain, and improve the content of heteroauxin in colon, serum and brain. The compound can be used for improving intestinal flora metabolism imbalance, improving mRNA levels of hippocampal neurogenin-2, synapsin and post-synaptic dense protein 95, maintaining neuronal synaptic function stability, activating AHR signal channels, improving bicortin DCX expression and promoting neurogenesis so as to relieve depression mood, and can be used for drugs, health care products or healthy food for preventing and treating depression.

The invention discloses a strain of lactobacillus pentosus JNL0030, application thereof and a microbial preparation, and belongs to the technical field of microorganisms. The lactobacillus pentosus JNL0030 is preserved in the China General Microbiological Culture Collection Center on June 24, 2024, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO: 31045, and the lactobacillus pentosus is classified and named as lactobacillus pentosus. The strain can realize high yield of indole-3-lactic acid in an MRS culture medium. An in-vitro experiment result shows that supernate of the strain remarkably inhibits inflammatory polarization of macrophages stimulated by lipopolysaccharide and secretion of inflammatory factors. Animal experiment results show that the strain can significantly inhibit sodium dextran sulfate induced colonic tissue inflammatory factor secretion and intestinal barrier injury, alleviate ulcerative colitis, and show a huge application value.

The invention discloses lactobacillus reuteri CCFM1288 for relieving depressive mood and application of the lactobacillus reuteri CCFM1288, and belongs to the technical field of microorganisms. The lactobacillus reuteri CCFM1288 has the tryptophan metabolism capability, and can survive for 7 days in the intestinal tract; after the lactobacillus reuteri CCFM1288 intervenes a depressive mouse, anxiety-like and depression-like behaviors of the mouse can be obviously relieved, flora alpha-diversity is improved, intestinal symbiotic bacteria are promoted to secrete indole substances, intestinal homeostasis is maintained, hypothalamic-pituitary-adrenal axis hyperfunction is relieved, dopamine and serotonin neurotransmitter nervous system functions are improved, and the effect of preventing and treating depression is achieved. The neurotransmitter release is promoted, and the anti-depression effect is achieved. In clinical tests, intervention of Lactobacillus reuteri CCFM1288 can significantly improve the depressive symptom of MDD patients, and a new safe alleviation approach is provided for depression treatment.

The invention discloses a shell nacre-derived anti-inflammatory active peptide and application thereof in preparation of a skin repair product. The inhibition rate of the active peptide GEIRYEYF provided by the invention on the NO release amount is concentration-dependent, and the NO release amount is reduced by 54.32 + / -2.13% under the concentration of 200 mu g / mL; in addition, secretion of RAW264.7 macrophage pro-inflammatory cytokines TNF-alpha and IL-6 can be remarkably reduced, secretion of anti-inflammatory cytokines IL-10 can be improved, dose dependence is achieved, under the highest concentration, the influence on IL-6 secretion is 47.76 + / -1.02%, the influence on TNF-alpha secretion is 42.01 + / -4.64%, the influence on IL-10 secretion is 41.71 + / -1.67%, and good anti-inflammatory activity is achieved. In addition, the bioactive peptide has a remarkable proliferation effect on L929 cells, and it is indicated that the bioactive peptide has the potential of promoting skin wound healing.

The invention discloses a toxoplasma gondii attenuated strain as well as a construction method and application thereof. The toxoplasma gondii attenuated strain delta MIC1 delta MIC3 disclosed by the invention is obtained by knocking out MIC1 and MIC3 genes from a TIR1 strain by utilizing a CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated 9) technology. The toxoplasma gondii attenuated strain delta MIC1 delta MIC3 can effectively enhance macrophage functions including phagocytic ability, proinflammatory factor secretion and the like, and provides theoretical basis and technical support for clarification of an immunoregulation network of toxoplasma gondii-host interaction and development of vaccine design based on attenuated strains.

The invention provides a hypoglycemic peptide which is prepared by taking bovine whey protein as a raw material and is stable in gastrointestinal digestion and absorption. In an in-vitro cell experiment, the peptide fragment can improve the uptake of insulin-resistant HepG2 hepatocytes and synthesize glycogen by using glucose, can promote intestinal endocrine cells NCI-H716 to secrete GLP-1, has a certain synergistic effect, and can further play the effects of promoting GLP-1 secretion and activating a GLP-1 receptor through combined use. An insulin resistance mouse model is constructed by utilizing high-fat diet, and the peptide fragment is adopted for intervention, so that the hypoglycemic peptide is further proved to have obvious effects on losing weight, reducing lipid accumulation and assisting in reducing blood fat, and meanwhile, the hypoglycemic peptide can be used for improving insulin resistance related symptoms. The milk peptide provided by the invention has gastrointestinal digestion stability and hypoglycemic activity, can be used as a functional milk base material for developing food, medicines or health care products with the effect of regulating blood sugar, and is wide in application prospect.

The invention discloses application of a Wnt2 gene in buffalo ovarian granular cells, and belongs to the technical field of cell engineering and gene engineering. Wnt2 is taken as a research object, the Wnt2 overexpression vector or Wnt2 siRNA is transfected to the ovarian granulosa cells respectively by constructing the Wnt2 overexpression vector and synthesizing small interfering RNA (Wnt2 siRNA), then changes of signal channel gene mRNA and protein level related to ovarian granulosa cell apoptosis, proliferation and E2 and P4 secretion are detected, and finally phenotypic changes of the ovarian granulosa cells are detected. Results show that Wnt2 can inhibit apoptosis of ovarian granular cells and promote proliferation and E2 and P4 secretion. By exploring the application of the Wnt2 in the ovarian granular cells, the application has good application in researching an ovarian follicle atresia mechanism, initial estrus initiation and the like.

The invention belongs to the field of biological medicines, and discloses an application of a stem cell extract in lysosome and mitochondrial related diseases, a preparation method of the stem cell extract comprises the following steps: S1) culturing mesenchymal stem cells and creating stress conditions to stimulate the mesenchymal stem cells; and S2) separating and purifying the culture supernatant of the mesenchymal stem cells cultured in the step S1) to obtain the stem cell extract, wherein S21) the culture supernatant is filtered to obtain a filtrate; s22) performing 3KD ultrafiltration concentration on the filtrate to obtain a crude sample; s23) purifying the crude sample by using molecular sieve exclusion chromatography or reversed-phase chromatography to prepare a purified sample; in molecular sieve exclusion chromatography, by taking the volume of the eluent as a reference, collecting the 10th to 40th mL of eluent, namely a purified sample; and S24) taking the purified sample to form a preparation. According to the application, the culture supernatant containing stress stem cell secretions is taken through stress culture of stem cells, and a purification method is combined, so that the prepared preparation can be used for treating lysosome and mitochondrial related diseases.

The invention belongs to the technical field of stem cell culture and exosome extraction, and provides an RELM beta pre-activated stem cell outer vesicle with high anti-inflammatory and anti-fibrosis activity. According to the method, the mesenchymal stem cells are subjected to hunger culture after being adhered to the wall and then are continuously cultured by a complete culture medium containing RELM beta factors, then supernate is collected, and the exovesicles are obtained through separation. In the preparation process of the extracellular vesicles, the paracrine function of MSC cells is promoted by the RELM beta, the secretion of anti-inflammatory and anti-fibrosis active factors is obviously activated, and the generation of the extracellular vesicles with enhanced anti-inflammatory and anti-fibrosis effects is promoted. Gene modification is not involved, toxic biochemical reagents or materials are not added, exogenous operation steps are simple and convenient, clinical application is guaranteed through sterile operation, no RELM beta residues exist after extracellular vesicle extraction, and the method is safe, non-toxic and effective.

The invention provides a CAR-NK cell for knocking out KIR2DL5 targeting HER2 as well as a preparation method and application of the CAR-NK cell, and belongs to the technical field of genetic engineering.The CAR-NK cell is obtained by adopting a chimeric antigen receptor with HER2 as a target spot to infect an NK cell and then knocking out a KIR2DL5 gene; the chimeric antigen receptor taking the HER2 as the target spot comprises an HER2 single-chain antibody; the nucleic acid artificial sequence of the HER2 single-chain antibody is as shown in SEQ ID NO. 2. According to the application disclosed by the invention, the interaction of KIR2DL5-PVR is blocked by knocking out NK cell immune checkpoints, so that tumor immune escape is avoided, and the activity of killing tumor cells by CAR-NK cells is remarkably enhanced; according to the invention, by optimizing the nucleic acid artificial sequence of HER2, the secretion ability of CAR-NK cell factors, the tumor killing efficiency and the in-vivo inhibition effect on tumors can be improved.

The invention discloses application of a metal boride nano material in preparation of an immunosuppressant, and belongs to the technical field of biological medicine. Specifically, through a series of researches, it is found that the metal boride nano material catalyzes an organic substrate containing a-CH-OH group in cells, and meanwhile, NAD (P) < + > is converted to generate NAD (P) H, GSH rising is promoted, and cell reductive stress is initiated. The immune cells are further induced to differentiate to an immunosuppressive phenotype, secretion of immunosuppressive factors is promoted, secretion of immune activating factors is inhibited at the same time, and finally the immunosuppressive effect is achieved. The catalytic action of the substance can provide a lasting and stable immunosuppression effect, and the feasibility of the substance in initiation of reduction stress and immunosuppression is proved through in-vivo and in-vitro experiments. The invention provides a new immunosuppression strategy, which is expected to make up the defects of the traditional immunosuppressor, and provides a new choice for related treatment of clinical organ transplantation, autoimmune diseases, inflammatory diseases and the like.

The invention discloses lactobacillus delbrueckii JNL0010, application of the lactobacillus delbrueckii JNL0010 and a microbial agent, and belongs to the technical field of microorganisms. The lactobacillus delbrueckii JNL0010 is preserved in the China General Microbiological Culture Collection Center on June 24, 2024, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, the preservation number is CGMCC NO: 31042, and the lactobacillus delbrueckii JNL0010 is classified and named as lactobacillus delbrueckii subsp.bulgaricus. The lactobacillus delbrueckii JNL0010 is named as lactobacillus delbrueckii subsp.bulgaricus. The strain can realize high yield of indole-3-lactic acid in an MRS culture medium. An in-vitro experiment result shows that supernate of the strain remarkably inhibits inflammatory polarization of macrophages stimulated by lipopolysaccharide and secretion of inflammatory factors. Animal experiment results show that the strain can significantly inhibit sodium dextran sulfate induced colonic tissue inflammatory factor secretion and intestinal barrier injury, alleviate ulcerative colitis, and show a huge application value.

The invention discloses a stem cell exosome based on targeted fusion polypeptide modification, a preparation method and application of the stem cell exosome in treating male erectile dysfunction. According to the exosome, a specific targeting fusion polypeptide (sequence: EPLQLKM-GGGS-DPPV) is anchored on the surface through a chemical coupling technology, so that the targeting property of the exosome on cavernosum smooth muscle cells is enhanced; meanwhile, an anti-TrkA monoclonal antibody (TrkA-2E7-HL) is loaded through an electroporation method, and a fibrosis pathway mediated by a nerve growth factor (NGF) is inhibited. The exosome induces secretion of the umbilical cord mesenchymal stem cells by adopting an anti-oxidation culture medium, so that the anti-oxidation activity of the exosome is remarkably improved. Experiments show that in a diabetes ED rat model, the erectile function (ICP / MAP ratio) of the modified exosome is improved to 0.79 + / -0.05, the fibrosis area is reduced to 9.2 + / -1.6%, and the NO secretion level is improved by 3.5 times compared with that of a common exosome. Through triple mechanisms of polypeptide targeting, antibody synergy and oxidation resistance, effective reversion of the ED pathological process is realized, and the polypeptide has remarkable novelty and clinical transformation potential.

The invention belongs to the technical field of gene engineering, and provides application of a magnaporthe oryzae Pmk1 protein K347 site as a target for inhibiting the pathogenicity of magnaporthe oryzae. Researches find that after the K347 site of the magnaporthe oryzae Pmk1 protein is mutated, the pathogenicity of magnaporthe oryzae is remarkably reduced, growth and expansion of magnaporthe oryzae hyphae can be inhibited, autophagy in the conidium germination process can be promoted, and secretion of effect protein of magnaporthe oryzae can be inhibited. Compared with the drug design aiming at the whole Pmk1 gene, the drug design aiming at the K347 site disclosed by the invention is accurate in range and has very high specificity and biological safety. The invention provides a new target site for developing a pyricularia grisea antibacterial drug, and the site has good application prospect and value in the aspect of preventing and controlling the rice blast.

The invention belongs to the field of biological medicine, and discloses an oral flora marker related to tongue squamous cell carcinoma (TSCC) and application of the oral flora marker. The oral cavity flora marker is Stomatobacterium longum (SBL), and the oral cavity flora marker is SBL (Stomatobacterium longum); the invention further discloses a diagnostic product of the TSCC, application of the SBL in preparation of a medicine for treating the TSCC and the medicine for treating the TSCC. The diagnosis product prepared by taking the SBL as the marker can quickly and effectively carry out early diagnosis on the TSCC so as to achieve the purposes of early discovery, early treatment and improvement of the survival rate. The medicine provided by the invention can specifically inhibit the SBL from secreting the nano extracellular vesicles so as to inhibit the expression of BRCA1 and further inhibit the expression of EXO1 and TP53BP1, so that the proliferation and cell cycle progress of TSCC cells are inhibited, and the treatment on the TSCC is realized. The medicine has good specificity and can be used for effectively treating TSCC.

The present application relates to the technical field of oat bran deep processing, and particularly relates to an oat active polypeptide with GLP-1 secretion promotion, blood sugar reduction and lipid reduction activity, and a preparation method and application thereof.The present application is prepared by adding alkaline protease and ficin for double-enzyme step-by-step hydrolysis after homogenate, enzymolysis and alkali extraction and acid precipitation pretreatment, and then filtering, ultrafiltration desalination and drying, so that the oat active polypeptide with GLP-1 secretion promotion, blood sugar reduction and lipid reduction activity is obtained.The present application is simple to operate, low in equipment requirement, and suitable for industrial large-scale production.The prepared oat active polypeptide has GLP-1 secretion promotion, blood sugar reduction and lipid reduction activity, has a significant inhibitory effect on pancreatic lipase and alpha-glucosidase, has an obvious GLP-1 secretion promotion effect, and has a significant blood sugar reduction and lipid reduction effect.

The invention provides a construction method and application of a blood sinus networked liver organ. According to the method, pluripotent stem cells are co-differentiated into HAND1 < + > mesoderm and endoderm, a front intestine rear endoderm containing KDR < + > mesoderm progenitor cells is generated, a liver endoderm with CD34 < + > / CD31 < + > endothelial progenitor cells is generated, and the blood sinus networked liver organ is formed. The liver organ has a functional blood sinus endothelial network penetrating through the liver cluster, and has the characteristic functions of low-density lipoprotein uptake, human serum albumin removal, mediated secretion of blood coagulation factor 8 and the like. The method provides a new-generation highly bionic research tool for liver disease mechanism analysis, drug screening and regeneration repair.

The invention discloses a method for increasing the yield of mesenchymal stem cell exosomes. A main culture medium used in the method is a human umbilical cord mesenchymal stem cell serum-free culture medium, and different natural compounds are respectively added in three main stages of mesenchymal stem cell growth, namely a recovery stage, an amplification stage and a stable stage, so that the characteristics of the mesenchymal stem cells in the stages are pertinently improved; the survival rate of the mesenchymal stem cells is protected in stages, the amplification efficiency of the mesenchymal stem cells is improved, the stability of the mesenchymal stem cells is maintained, and the exosome secretion amount of the mesenchymal stem cells can be remarkably increased through combined use of the three natural compounds. According to the invention, the secretion amount of the exosome of the mesenchymal stem cells can be obviously increased, and the problem of low yield of the mesenchymal stem cells at present is solved.

The invention discloses a fish by-product active peptide, a preparation and application, and belongs to the technical field of biological active peptides. The amino acid sequences of the fish by-product active peptide are shown as SEQ ID NO: 1 to SEQ ID NO: 3. Both the single peptide fragment and the compound peptide fragment of the fish by-product active peptide can obviously inhibit NO secretion of a lipopolysaccharide (LPS)-induced macrophage (RAW264.7) inflammation model, so that the fish by-product active peptide has a relatively good application prospect in preparation of a product with an anti-inflammatory effect; and a foundation is laid for high-added-value utilization of salmon byproducts and promotion of research, development and application of functional active peptides.

The present invention relates to the field of stem cell technology. The present invention discloses a method for inducing stem cells to secrete specific factors, which includes stimulating stem cells with high-frequency waves, emitting sound waves of a specific frequency to stem cells, regulating stem cells in a hypoxic environment, culturing stem cells in a hypoxic environment, stimulating stem cells with oxidative stress, and subjecting stem cells to oxidative stimulation treatment. The present invention can significantly enhance the proliferation ability of stem cells, promote the secretion of multiple active factors, and improve cell function and adaptability. As a non-invasive physical method, high-frequency wave stimulation can activate internal cell signal pathways without introducing exogenous substances, significantly improving the proliferation ability and tissue repair potential of stem cells. Hypoxic environment regulation simulates the naturally existing microenvironmental conditions in the body, greatly promoting the secretion of active factors such as vascular endothelial growth factor, basic fibroblast growth factor, and brain-derived neurotrophic factor for tissue repair and immune regulation.

The invention discloses a neutralizing nucleic acid aptamer for targeted inhibition of a B cell activating factor and application of the neutralizing nucleic acid aptamer in treatment of systemic lupus erythematosus. The neutralizing aptamer disclosed by the invention can be used for efficiently inhibiting the combination of BAFF and specific receptors on a B cell membrane, including a BAFF receptor (BAFF-R), a human calcium regulatory cyclophilin ligand interaction molecule (TACI) and a B cell maturation antigen (BCMA), so that the proportion of plasma cells, plasma mother cells and hair growth center B cells is reduced, and finally, the generation and secretion of autoantibodies are reduced; the compound has a targeted therapeutic effect on systemic lupus erythematosus. Compared with an existing biological agent for neutralizing BAFF, the neutralizing nucleic acid aptamer has the advantages of being high in specificity, high in affinity, easy to synthesize, low in immunogenicity, low in cost, capable of being designed and programmed and the like, is a potential novel nucleic acid preparation for SLE targeted therapy, and has a good clinical transformation application prospect.

The invention belongs to the technical field of protein, and relates to an anti-inflammatory active peptide as well as a preparation method and application thereof. The amino acid sequence of the anti-inflammatory peptide is LLVK. The anti-inflammatory peptide fragment is spontaneously combined with I kappa B protein through hydrogen bonds and hydrophobic interaction to form a more stable compound, phosphorylation of the I kappa B protein is inhibited, secretion of inflammatory factors IL-1beta, IL-6 and TNF-alpha and a chemotactic factor MCP-1 is reduced, and therefore inflammatory reaction is prevented. The invention also provides a preparation method and application of the anti-inflammatory active peptide.

Disclosed herein are modified strains for improving secretion of recombinantly expressed products secreted from a host organism with improved growth and productivity characteristics, as well as methods of using the modified strains.